Surgical treatment of recurrent retroperitoneal sarcoma in its different patterns: A 15-years' two-centers experience.


Journal

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
ISSN: 1479-666X
Titre abrégé: Surgeon
Pays: Scotland
ID NLM: 101168329

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 26 11 2022
revised: 10 01 2023
accepted: 10 01 2023
medline: 20 9 2023
pubmed: 28 1 2023
entrez: 27 1 2023
Statut: ppublish

Résumé

There is limited data available regarding the role of surgery in the treatment of retroperitoneal sarcoma (RPS) recurrences. We herein report the short- and mid-term outcomes of patients who underwent surgical treatment of RPS recurrences at two Italian centers over a 15-years' experience. From January 2005 to January 2020, 33 patients underwent surgical treatment of isolated locally recurrent RPS (LR group), locally recurrent RPS associated with the presence of distant recurrence (LR + DM group), and distant-only recurrent RPS (DM group). Only procedures performed to obtain a macroscopically radical treatment with curative intent were included. Data regarding pre-, intra-, post-operative course, and follow-up, collected in an Institutional database, were retrospectively analyzed, and compared. LR-group was composed of 15 patients, LR + DM group of 9 patients, and DM group of 9 patients. During the follow-up, 78.5% of the LR group, 77.8% of the DM group and 100% of the LR + DM group (p = 0.244) experienced a second recurrence. 7/11 (63.6%) patients in the LR group, 2/7 (28.5%) patients in the DM-group, and 0/9 (0.0%) patients in the LR + DM group underwent to almost one further local treatments of their recurrences (p = 0.010). No differences in the mean disease-free survival (p = 0.127), overall survival (OS) (p = 0.165) was reported among the three groups. Repeated surgery was an independent factor affecting survival in multivariate analysis (p = 0.01). A surgical treatment of RPS recurrences should always be taken into consideration, also in metastatic patients and/or in those who have already undergone surgery for previous RPS recurrence, because this approach may offer survival benefits.

Identifiants

pubmed: 36707317
pii: S1479-666X(23)00004-5
doi: 10.1016/j.surge.2023.01.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e249-e257

Informations de copyright

Copyright © 2023 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of Interest The authors declare that they have no conflict of interest.

Auteurs

Simone Guadagni (S)

General Surgery Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

Andrea Peri (A)

Department of Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Matteo Palmeri (M)

General Surgery Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. Electronic address: matteo.palmeri@med.unipi.it.

Niccolò Furbetta (N)

General Surgery Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

Gregorio Di Franco (G)

General Surgery Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

Matteo Filardo (M)

Department of Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Annalisa Comandatore (A)

General Surgery Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

Luca Emanuele Pollina (LE)

Second Division of Surgical Pathology, University Hospital of Pisa, Italy.

Raffaele Gaeta (R)

Second Division of Surgical Pathology, University Hospital of Pisa, Italy.

Andrea Sbrana (A)

Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.

Luca Galli (L)

Unit of Oncology 2, University Hospital of Pisa, Italy.

Chiara Mercinelli (C)

Unit of Oncology 2, University Hospital of Pisa, Italy.

Andrea Pietrabissa (A)

Department of Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Giulio Di Candio (G)

General Surgery Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

Luca Morelli (L)

General Surgery Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH